Results 271 to 280 of about 62,474 (297)

The Future of Neovascular Age-Related Macular Degeneration [PDF]

, 2011
The treatment of neovascular age-related macular degeneration (AMD) will continue to evolve dramatically. Researchers are working to find new therapeutics targeting important pathways involved in angiogenesis, including: Vascular endothelial growth factor (VEGF) inhibition Vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth ...
Chirag P. Shah, Jeffrey S. Heier
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Aflibercept for the treatment of neovascular age-related macular degeneration

Drugs of Today, 2012
Age-related macular degeneration (AMD) can have devastating effects on vision, especially in its neovascular form. In the last decade, the use of intravitreal pharmacotherapy targeted to vascular endothelial growth factor (VEGF) has significantly improved the visual outcomes in patients with neovascular AMD.
Stephen J. Davis, Andreas K. Lauer, E. A. Verner-Cole   +2 more
openaire   +3 more sources

Innovative therapies for neovascular age-related macular degeneration

Expert Opinion on Pharmacotherapy, 2019
Introduction: Investigational anti-VEGF treatments for neovascular age-related macular degeneration (nAMD) aim to improve visual outcomes and reduce treatment burden; these include long-acting agents, combination strategies, topical agents, sustained-release, and genetic therapies.
Thomas A. Ciulla, Pravin U. Dugel, Hasenin Al-khersan, Rehan M. Hussain   +3 more
openaire   +3 more sources

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: ROUNDTABLE

Retina, 2005
Several recent developments may provide an opportunity to improve outcome in individuals who develop neovascular age-related maculopathy (age-related macular degeneration [ARMD]). Concurrent with progress in isolating clinically relevant subtypes of neovascular ARMD, several therapies have been introduced that show promise for halting progression of ...
Jennifer I. Lim, Andrew P. Schachat, Richard F. Spaide, Lawrence J. Singerman, Alexander J. Brucker, Philip J. Rosenfeld, Lee M. Jampol   +6 more
openaire   +2 more sources

OCT‐A in neovascular age related macular degeneration

Acta Ophthalmologica, 2016
SummaryThe author reports regression and progression of CNV after treatment. Normal cycle lasts about 70 days. Abnormal recurrences are reported.
openaire   +2 more sources

JUNB‐FBXO21‐ERK axis promotes cartilage degeneration in osteoarthritis by inhibiting autophagy

Aging Cell, 2021
Lunhao Bai, Zhiming Lin
exaly  

SIRT3 mitigates intervertebral disc degeneration by delaying oxidative stress‐induced senescence of nucleus pulposus cells

Journal of Cellular Physiology, 2021
Dechun Geng, Haiqing Mao, Jiayi Lin
exaly  

Single‐Cell Transcriptome Profiling Reveals Multicellular Ecosystem of Nucleus Pulposus during Degeneration Progression

Advanced Science, 2022
W Li, Justin J Cooper-white, Ji Tu
exaly  

m6A hypomethylation of DNMT3B regulated by ALKBH5 promotes intervertebral disc degeneration via E4F1 deficiency

Clinical and Translational Medicine, 2022
Gaocai Li, Bingjin Wang, Xiaobo Feng
exaly  

Macular atrophy development in neovascular age-related macular degeneration

European Journal of Ophthalmology, 2020
Dan Călugăru, Mihai Călugăru
openaire   +3 more sources